This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
The majority of serpin diseases are due to protein aggregation and are termed "serpinopathies". Serpins are vulnerable to disease-causing mutations that promote formation of misfolded polymers due to their inherently unstable structures. Well-characterised serpinopathies include α1-antitrypsin deficiency (alpha-1), which may cause familial emphysema, and sometimes liver cirrhosis, certain familial forms of thrombosis related to antithrombin deficiency, types 1 and 2 hereditary angioedema (HAE) related to deficiency of C1-inhibitor, and familial encephalopathy with neuroserpin inclusion bodies (FENIB; a rare type of dementia caused by neuroserpin polymerisation). Each monomer of the serpin aggregate exists in the inactive, relaxed conformation (with the RCL inserted into the A-sheet). The polymers are therefore hyperstable to temperature and unable to inhibit proteases. Serpinopathies therefore cause pathologies similarly to other proteopathies (e.g. prion diseases) via two main mechanisms. First, the lack of active serpin results in uncontrolled protease activity and tissue destruction. Second, the hyperstable polymers themselves clog up the endoplasmic reticulum of cells that synthesize serpins, eventually resulting in cell death and tissue damage. In the case of antitrypsin deficiency, antitrypsin polymers cause the death of liver cells, sometimes resulting in liver damage and cirrhosis. Within the cell, serpin polymers are slowly removed via degradation in the endoplasmic reticulum.
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography.
The Albany facility is the company's main research and development site in the industry, and has recently partnered with Seattle-based technology company EnerG2 to produce carbon electrode material, in a 74,000-square-foot (6,900 m2) former distribution center of Oregon Freeze Dry by 2011 bringing a new green technology industry to Albany. Tec Laboratories has made Tecnu poison ivy cleanser and other topical medicines in Albany since 1977. Albany is also home to the Albany Research Center, which is part of National Energy Technology Laboratory (NETL). They employ a staff of 120. Albany Research Center was founded in 1943, the laboratory specializes in life cycle research starting with the formulation, characterization, and/or melting of most metals, alloys, and ceramics; casting and fabrication, prototype development; and the recycle and remediation of waste streams associated with these processes. The Heritage Mall, an enclosed shopping center, opened on November 2, 1988. The construction of a regional shopping center had been planned for a decade and included proposals to build a rival mall in Corvallis.
Sources: en.wikipedia.org
Many different emulsifiers are used in pharmacy to prepare emulsions such as creams and lotions. Common examples include emulsifying wax, polysorbate 20, and ceteareth 20. Sometimes the inner phase itself can act as an emulsifier, and the result is a nanoemulsion, where the inner state disperses into "nano-size" droplets within the outer phase. A well-known example of this phenomenon, the "ouzo effect", happens when water is poured into a strong alcoholic anise-based beverage, such as ouzo, pastis, absinthe, arak, or raki. The anisolic compounds, which are soluble in ethanol, then form nano-size droplets and emulsify within the water. The resulting color of the drink is opaque and milky white.
=== Prognosis === Most emetic patients recover within 6 to 24 hours, but in some cases, the toxin can be fatal via fulminant hepatic failure. In 2014, 23 newborns in the UK receiving total parenteral nutrition contaminated with B. cereus developed sepsis, with three of the infants later dying as a result of infection.
== Prevention == Prevention approaches for opioid use disorder must consider clinical recommendations for prescribing/starting to take opioids, when they are clinically appropriate to use, and risks associated with opioid therapy. Improving opioid prescribing guidelines and practices can help reduce unnecessary exposure to opioids, which lowers the risk of developing OUD (opioid use disorder). Healthcare providers should strictly follow evidence-based guidelines to ensure safe and appropriate use. Another way to prevent OUD is by educating the public about the risks of prescription opioids and illegal substances like fentanyl. Awareness campaigns, community outreach programs, and school-based education initiatives can help people make informed decisions about opioid use and recognize the signs of addiction early. Promoting the disposal of unused opioid doses also helps prevent OUD. A strong association between adverse childhood experiences and opioid abuse later in life has been identified, suggesting that a high adverse childhood experiences score should be considered a risk factor for opioid abuse. Screening for adverse childhood experiences before prescribing or implementing interventions involving opioids can mitigate the potential for misuse.
Sources: en.wikipedia.org
=== Nobel Prize in Physiology or Medicine (1923) === In October 1923, Banting and Macleod were jointly awarded the 1923 Nobel Prize in Physiology or Medicine "for the discovery of insulin". Within a month of the award ceremony, Banting had given Best one-half of his share in the $US24,000 prize, and Macleod had given Collip one-half of his share.
Returning to Los Angeles, Parsons sought out Chris Hillman, and the two formed The Flying Burrito Brothers with bassist Chris Ethridge and pedal steel player Sneaky Pete Kleinow. Their 1969 album The Gilded Palace of Sin marked the culmination of Parsons' post-1966 musical vision: a modernized variant of the Bakersfield sound that was popularized by Buck Owens amalgamated with strands of soul and psychedelic rock. The band appeared on the album cover wearing Nudie suits emblazoned with hippie symbols, including marijuana, Tuinal, and Seconal-inspired patches. Along with the Parsons-Hillman originals "Christine's Tune" and "Sin City" were versions of the soul music classics "The Dark End of the Street" and "Do Right Woman, Do Right Man", the latter featuring David Crosby on high harmony. The original songs were the result of a productive songwriting partnership between Parsons and Hillman, who were sharing a bachelor pad in the San Fernando Valley. The pronounced gospel-soul influence on this album likely evolved from the ecumenical tastes of bassist Chris Ethridge, who co-wrote "Hot Burrito No. 1/I'm Your Toy" and "Hot Burrito No. 2" with Parsons. Original drummer Eddie Hoh was unable to perform adequate takes due to a substance abuse problem. He was dismissed after two songs and the band used session drummers, including former International Submarine Band drummer Jon Corneal and Popeye Phillips. Before commencing live performances, the group settled on original Byrds drummer Michael Clarke. The Gilded Palace of Sin was commercially unsuccessful.
=== Chinese communities under colonial rule === Chinese communities living in colonial port cities were influenced by the diverse cultures they encountered, which also led to evolving understandings of medical practices where Chinese forms of medicine were combined with Western medical knowledge. For example, the Tung Wah Hospital was established in Hong Kong in 1869 based on the widespread rejection of Western medicine for pre-existing medical practices, although Western medicine would still be practiced in the hospital alongside Chinese medicinal practices. The Tung Wah Hospital was likely connected to another Chinese medical institution, the Kwong Wai Shiu Hospital of Singapore, which had previous community links to Tung Wah, was established for similar reasons, and also provided both Western and Chinese medical care. By 1935, English-language newspapers in Colonial Singapore already used the term "Traditional Chinese Medicine" to label Chinese ethnic medical practices. In the Chinese Communist Party-controlled areas prior to the founding of the People's Republic of China, there was a lack of access to Western-style medical resources. To improve health care, the Chinese Communist Party (CCP) promoted the integration of traditional Chinese medicine with Western medical science. In the Yan'an Soviet, mass campaigns sought to "scientize Chinese medicine" and "make Western medicine Chinese."
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.